Bristol-Myers Squibb Company (BMY - Free Report) suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its primary endpoint.
The phase III randomized, multi-center study CheckMate -548 is evaluating the addition of Opdivo to the current standard of care (Temodal and radiation therapy) compared to the standard of care alone in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated.
However, the study did not meet the primary endpoint of progression-free survival (PFS) per blinded independent central review (BICR).
Nevertheless, the data monitoring committee recommended that the study continue as planned to allow the other primary endpoint, overall survival (OS), is yet to mature. The company remains blinded to all study data. The secondary endpoints are investigator assessed PFS, and OS rate up to two years.
Earlier, the phase III CheckMate-498 trial evaluating Opdivo plus radiation compared to temozolomide plus radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM missed its primary goal of overall survival at final analysis.
Bristol-Myers’ shares have decreased 6.7% in the year so far, wider than the industry’s decline of 0.6%.
Meanwhile, Karyopharm Therapeutics (KPTI - Free Report) is also evaluating Xpovio for the treatment of glioblastoma.
Opdivo is Bristol-Myers’ primary driver. It is currently approved in the United States, the EU, Japan and across other countries for several cancer indications. The company is working on expanding the label of Opdivo further.
However, the drug faces stiff competition and has endured debacles of late. It confronts rivalry from Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda. Additionally, a close contest is on the rise in this category with the presence of Roche’s (RHHBY - Free Report) Tecentriq. Both Keytruda and Tecentriq are approved for the first-line non-small cell lung cancer (NSCLC), which has the largest patient population among all cancer indications.
We remind investors that the part 1a of the phase III Checkmate-227 study evaluating Opdivo combined with low-dose Yervoy compared to chemotherapy only, succeeds in meeting the co-primary endpoint of overall survival in first-line NSCLC patients whose tumors express PD-L1 ≥1%. However, part 2 of the study evaluating Opdivo plus chemotherapy compared to chemotherapy alone was unable to meet its primary endpoint of overall survival in first-line non-squamous NSCLC patients, regardless of PD-L1 status.
Bristol-Myers currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Bristol-Myers Squibb Company (BMY - Free Report) suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its primary endpoint.
The phase III randomized, multi-center study CheckMate -548 is evaluating the addition of Opdivo to the current standard of care (Temodal and radiation therapy) compared to the standard of care alone in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated.
However, the study did not meet the primary endpoint of progression-free survival (PFS) per blinded independent central review (BICR).
Nevertheless, the data monitoring committee recommended that the study continue as planned to allow the other primary endpoint, overall survival (OS), is yet to mature. The company remains blinded to all study data. The secondary endpoints are investigator assessed PFS, and OS rate up to two years.
Earlier, the phase III CheckMate-498 trial evaluating Opdivo plus radiation compared to temozolomide plus radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM missed its primary goal of overall survival at final analysis.
Bristol-Myers’ shares have decreased 6.7% in the year so far, wider than the industry’s decline of 0.6%.
Meanwhile, Karyopharm Therapeutics (KPTI - Free Report) is also evaluating Xpovio for the treatment of glioblastoma.
Opdivo is Bristol-Myers’ primary driver. It is currently approved in the United States, the EU, Japan and across other countries for several cancer indications. The company is working on expanding the label of Opdivo further.
However, the drug faces stiff competition and has endured debacles of late. It confronts rivalry from Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda. Additionally, a close contest is on the rise in this category with the presence of Roche’s (RHHBY - Free Report) Tecentriq. Both Keytruda and Tecentriq are approved for the first-line non-small cell lung cancer (NSCLC), which has the largest patient population among all cancer indications.
We remind investors that the part 1a of the phase III Checkmate-227 study evaluating Opdivo combined with low-dose Yervoy compared to chemotherapy only, succeeds in meeting the co-primary endpoint of overall survival in first-line NSCLC patients whose tumors express PD-L1 ≥1%. However, part 2 of the study evaluating Opdivo plus chemotherapy compared to chemotherapy alone was unable to meet its primary endpoint of overall survival in first-line non-squamous NSCLC patients, regardless of PD-L1 status.
Bristol-Myers currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RHHBY - FREE
Get the latest research report on BMY - FREE
Get the latest research report on MRK - FREE
Get the latest research report on KPTI - FREE